X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Under the agreement, SOTIO will leverage Synaffix’s antibody-drug conjugate platform for the design of up to three novel ADCs targeting distinct tumor-associated antigens.
Lead Product(s): Undisclosed
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Discovery PlatformProduct Type: Large molecule
Recipient: Synaffix
Deal Size: $740.0 million Upfront Cash: Undisclosed
Deal Type: Licensing Agreement October 16, 2023
Details:
SOT101 (nanrilkefusp alfa) is an IL-15 superagonist that is fused to the sushi+ domain of the IL-15 receptor alpha chain. IL-15 activity increases the number of cytotoxic T cells and NK cells, which shows anti-cancer immune response.
Lead Product(s): Nanrilkefusp Alfa,Cetuximab
Therapeutic Area: Oncology Product Name: SOT101
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 13, 2023
Details:
SOT102 is a potent antibody-drug conjugate that combines the clinically-validated target Claudin 18.2 (CLDN18.2) with a powerful toxin to address gastric, pancreatic and other cancers that have very few targeted treatments available.
Lead Product(s): SOT102,Paclitaxel,Gemcitabine
Therapeutic Area: Oncology Product Name: SOT102
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 11, 2023
Details:
SOT101 (nanrilkefusp alfa) is a subcutaneously administered IL-15 superagonist that is fused to the sushi+ domain of the IL-15 receptor alpha chain. IL-15 activity increases the number of cytotoxic T cells and NK cells, which shows anti-cancer immune response.
Lead Product(s): Nanrilkefusp Alfa,Cetuximab
Therapeutic Area: Oncology Product Name: SO-C101
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 19, 2023
Details:
SOT106 is a novel ADC based on SOTIO Biotech’s proprietary antibodies and LCB’s industry-leading ConjuAll™ ADC platform technology with potential best-in class efficacy, safety and tolerability currently in preclinical development against multiple solid tumor indications.
Lead Product(s): SOT106
Therapeutic Area: Oncology Product Name: SOT106
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: LegoChem Biosciences
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement November 29, 2022
Details:
SOT101 (formerly SO-C101) (RLI-15) is a subcutaneously-administered IL-15 superagonist that is fused to the IL-15α chain receptor. SOT101 is designed to selectively bind only to cytotoxic T and NK cells, while avoiding other cell types that are associated with adverse events.
Lead Product(s): SOT101,Pembrolizumab
Therapeutic Area: Oncology Product Name: SO-C101
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 18, 2022
Details:
SOT101 (SO-C101) is subcutaneously administered IL-15R superagonist that is fused to sushi+ domain of IL-15 receptor α chain, demonstrated strong preclinical in vivo efficacy in various tumor models showing increased tumor regression, as well as favorable toxicology profile.
Lead Product(s): SOT101,Pembrolizumab
Therapeutic Area: Oncology Product Name: SO-C101
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 26, 2022
Details:
The adverse event profile of SOT101 in combination with pembrolizumab was in line with the adverse event profile of either compound as monotherapy. No additive toxicity was seen when combining SOT101 with pembrolizumab.
Lead Product(s): SOT101,Pembrolizumab
Therapeutic Area: Oncology Product Name: SO-C101
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 26, 2022
Details:
AURELIO-03 is a Phase 1/1b dose escalation study of SOT101(formerly SO-C101) (RLI-15) is a subcutaneously-administered IL-15 superagonist that is fused to IL-15α chain receptor.as monotherapy and in combination with pembrolizumab in patients with advanced solid tumors.
Lead Product(s): SOT101,Pembrolizumab
Therapeutic Area: Oncology Product Name: SOT101
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 27, 2022
Details:
SOT102 is a CLDN18.2 targeting highly specific mAB conjugated to a potent cytotoxic drug molecule, Preclinical data from studies of SOT102 have demonstrated potent anti-tumor efficacy in vitro and in vivo due to NBE’s proprietary site-specific SMAC conjugation platform.
Lead Product(s): SO-N102
Therapeutic Area: Oncology Product Name: SOT102
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 26, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
